Vertex in deal with Lonza for facility to produce cell-based diabetes therapies
Monty Rakusen/DigitalVision via Getty Images         
Vertex Pharmaceuticals (NASDAQ:VRTX) is in an agreement with Lonza to build a new manufacturing facility in Portsmouth, N.H., that will make the former's islet cell therapies for type 1 diabetes.
The facility is expected to have more than 130,000 square feet of space and add up to 300 new jobs. Construction start is slated for later this year.
Vertex currently has two islet cell therapies for T1D in the clinic, VX-880 and VX-264. Both are in phase 1/2.

More on Vertex

Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape
Vertex Pharmaceuticals Rally Likely Not Over